etodolac has been researched along with Ulcer in 6 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aims of the present study were to determine, in rats, the role of neutrophils in the pathogenesis of etodolac- and indomethacin-induced gastrointestinal ulceration and blood loss." | 7.69 | Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat. ( Fuller, J; Gentry, C; Melarange, R; Smith, PH; Toseland, CD, 1995) |
| " Clinical experience shows etodolac, 300 mg twice daily, given to elderly patients with osteoarthritis for 4 weeks, to be effective and well tolerated in this population." | 4.79 | Special considerations in the use of NSAIDs in the elderly. ( Todesco, S, 1994) |
| " The aims of the present study were to determine, in rats, the role of neutrophils in the pathogenesis of etodolac- and indomethacin-induced gastrointestinal ulceration and blood loss." | 3.69 | Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat. ( Fuller, J; Gentry, C; Melarange, R; Smith, PH; Toseland, CD, 1995) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) that has shown a favorable safety profile in clinical trials in osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.68 | Global safety of etodolac: reports from worldwide postmarketing surveillance studies. ( Serni, U, 1990) |
| "Nabumetone proved to be an effective anti-inflammatory agent that was devoid of gastrointestinal irritancy." | 1.29 | Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. ( Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD, 1994) |
| " The elderly appear to be no more at risk of experiencing adverse effects than the general population." | 1.28 | An updated safety profile of etodolac in several thousand patients. ( Schattenkirchner, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvo, N | 1 |
| Iversen, E | 1 |
| Munck, LK | 1 |
| Todesco, S | 1 |
| Melarange, R | 2 |
| Gentry, C | 2 |
| Blower, PR | 1 |
| Toseland, CD | 2 |
| Spangler, R | 1 |
| Smith, PH | 1 |
| Fuller, J | 1 |
| Schattenkirchner, M | 1 |
| Serni, U | 1 |
1 review available for etodolac and Ulcer
| Article | Year |
|---|---|
Special considerations in the use of NSAIDs in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Etodolac; Female; Humans; Kidney; M | 1994 |
5 other studies available for etodolac and Ulcer
| Article | Year |
|---|---|
[Intestinal side effects of COX-2 inhibitors].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; | 2006 |
Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carr | 1994 |
Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antilymphocyte Serum; Etodolac; Gastric Mucosa; Ga | 1995 |
An updated safety profile of etodolac in several thousand patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Gastrointestinal Diseases; Hematolog | 1990 |
Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 1990 |